Katerzia FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 6, 2019.
FDA Approved: Yes (First approved July 8, 2019)
Brand name: Katerzia
Generic name: amlodipine benzoate
Dosage form: Oral Suspension
Company: Azurity Pharmaceuticals, Inc.
Treatment for: High Blood Pressure, Coronary Artery Disease
Katerzia (amlodipine benzoate) is a calcium channel blocker in an oral suspension formulation indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, and coronary artery disease in adults.
Development timeline for Katerzia
| Date | Article |
|---|---|
| Jul 10, 2019 | Approval FDA Approves Katerzia (amlodipine) Oral Suspension for Pediatric Patients 6 Years of Age and Older |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
